Company intelligence / Profile preview

Pluvia Biotech

Bergen, Norwaypluviabiotech.com ↗
Ownership
Private
Development stage
Other
01

Overview

Pluvia Biotech is developing small molecule pharmacological chaperones to treat rare genetic diseases caused by protein misfolding, with a lead program for phenylketonuria (PKU). Their lead compound PBAS499 has received Orphan Drug and Rare Pediatric Disease Designations from the FDA and is progressing toward clinical proof of concept. Preclinical data have been presented at major scientific meetings, and a key patent application has been published[2][7].

Therapeutic areas
Metabolic Disorders
Modalities
Small moleculePharmacological chaperone
Industry
Biotech
02

Drug pipeline

2 assets

Pluvia Biotech PAH chaperone

Preclinical

1 more asset in the full pipeline.

03

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed as of June 2025. There is mention of collaboration with PTC Therapeutics regarding sepiapterin development for PKU in partnership context but not as a formal partnership[2].

Beyond the preview

Go deeper on Pluvia Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pluvia Biotech.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call